http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017526630-A

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-3809
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
filingDate 2015-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2017-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2017526630-A
titleOfInvention Specific binding partner for vitamin D epimer
abstract Antibodies are raised against compounds of formula (I) wherein Z is an immunogenic carrier. These compounds can specifically bind to the corresponding antibody. The antibody is specific for an epimer of vitamin D. By using antibodies in accordance with the principles described herein, cross-reactivity with 3-epimers in assays of non-epimeric vitamin D analytes can be minimized or eliminated. Overestimation of all non-epimer vitamin D analytes due to cross-reactivity of 3-epimer vitamin D and antibodies against vitamin D analytes is a compound of formula (I) where Z is This can be substantially avoided by using an antibody prepared using an immunogenic carrier) as an immunogen. (R1) p- (L) q-Z (I) [Selection] Figure 1
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021100841-A1
priorityDate 2014-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012162165-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466800666

Total number of triples: 18.